Inotropic agents and infarct size. Theoretical and practical considerations.
Recent data demonstrating the ability of interventions that alter the balance between myocardial oxygen demand and supply to affect infarct size are reviewed. The effects of inotropic agents on the determinants of myocardial oxygen consumption and coronary blood flow are discussed relative to the potential of these drugs to decrease or increase infarct size in the experimental animal and in man. The applicability of the animal data to the clinical situation is discussed and, on the basis of these considerations, guidelines are presented for the use of inotropic agents in patients with acute myocardial infarction.
D000208:Acute Disease; D000818:Animals; D002306:Cardiac Volume / Q000187:drug effects; D004071:Digitalis Glycosides / Q000494:pharmacology*; D006321:Heart / Q000503:physiopathology; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007545:Isoproterenol / Q000494:pharmacology*; D009200:Myocardial Contraction / Q000187:drug effects*; D009203:Myocardial Infarction / Q000150:complications / Q000378:metabolism / Q000473:pathology*; D009638:Norepinephrine / Q000494:pharmacology*; D010100:Oxygen / Q000097:blood; D010101:Oxygen Consumption / Q000187:drug effects; D011312:Pressure
D004071:Digitalis Glycosides; D007545:Isoproterenol; D010100:Oxygen; D009638:Norepinephrine